Drug Manufacture FDA Approves Rexulti for Alzheimer’s AgitationBy MohamedMis2July 21, 2023 Alzheimer’s disease, a distressing and degenerative condition, can lead to troubling symptoms like agitation. However, there is now a glimmer…
Financial Advancing Towards Myelofibrosis BreakthroughBy MohamedMis2July 12, 2023 MorphoSys is on track to complete its Phase 3 myelofibrosis program 16% faster than originally planned. [1] However, there is…
